Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.37 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.32 |
| ▸ | APAF1 | O14727 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12749119 | 0.97 | PDE7A (0.40) | PDE7AMGAT2CES1KDM4EMEN1 | |
| SCHEMBL12749058 | 0.94 | CES1 (0.38) | PDE7AMGAT2CES1KDM4EMEN1 | |
| SCHEMBL13757008 | 0.85 | PDE7A (0.41) | PDE7AMGAT2CES1 | |
| SCHEMBL13802638 | 0.82 | PDE7A (0.44) | PDE7AMGAT2CES1 | |
| SCHEMBL13802645 | 0.78 | PDPK1 (0.40) | PDE7ACES1 | |
| SCHEMBL12749338 | 0.76 | MOGAT2 (0.38) | MGAT2CES1MEN1MAPTKMT2A | |
| SCHEMBL1270125 | 0.74 | CES1 (0.48) | CES1MEN1MAPTKMT2AUSP2 | |
| SCHEMBL19225163 | 0.73 | PDE7A (0.47) | PDE7AMGAT2KDM4EMEN1KMT2A | |
| SCHEMBL5975593 | 0.71 | CES1 (0.60) | CES1MEN1MAPTKMT2APTPRC | |
| SCHEMBL10758073 | 0.68 | PDE7A (0.54) | PDE7AKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989198-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007096351-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PDE7A 1406/4885MGAT2 3320/4885CES1 703/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PDE7A 1406/4885MGAT2 3320/4885CES1 703/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PDE7A 1406/4885MGAT2 3320/4885CES1 703/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | PDE7A 3687/4885MGAT2 2911/4885CES1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.